Seeking Alpha

ADC Therapeutics SA (ADCT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Good morning, everyone. My name is [Mary Lou], and I'm one of the associates on the healthcare investment banking team at JPMorgan. It's my pleasure to introduce our next presentation from ADC ...
Seeking Alpha

Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with ...

The spliceosome targeting payload, PH1, demonstrates the ability to induce both cancer cell cytotoxicity and activation of anti-tumor immunity through multiple mechanisms Treatment with a ...
Morningstar

Daiichi Sankyo Presents New Data in Small Cell Lung Cancer and Updates Across ADC Portfolio Highlighting Progress in Creating New Standards of Care for Patients with Lung ...

Late-breaking data from IDeate-Lung01 phase 2 trial demonstrate potential of ifinatamab deruxtecan to become first-in-class B7-H3 directed ADC for pretreated extensive-stage small cell lung cancer ...
BioWorld

ADC Therapeutics presents new anti-ASCT2 conjugates

ADC Therapeutics SA has synthesized antibody-drug conjugates comprising antibody targeting neutral amino acid transporter B (0) (SLC1A5; ASCT2) covalently linked to exatecan through a linker reported ...
WAVY-TV

Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting

INDIANAPOLIS, June 2, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its folate receptor alpha (FRα) antibody-drug conjugate (ADC) (LY4170156) ...